Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States.
The product Is the generic equivalent of BENADRYL®, as approved by the U.S. Food and Drug Administration, and is indicated for the treatment of allergic reactions, including as an adjunct in anaphylaxis after acute symptoms have been controlled, for motion sickness, and for certain cases of parkinsonism when oral therapy is not feasible. Each vial of Diphenhydramine Hydrochloride Injection, USP contains 50 mg per 1 mL (50 mg per mL) and is available as a carton of 25 single-dose vials.
“Since launching Avenacy in October 2023, we have remained focused on building a reliable portfolio of essential injectable medications that hospitals depend on every day to deliver consistent care to patients,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “The addition of Diphenhydramine Hydrochloride Injection marks our 26th product offering and our first launch of 2026. We look forward to continuing to strengthen our portfolio with critical injectable medicines.”
In line with Avenacy’s mission to champion patient safety and streamline patient care, Diphenhydramine Hydrochloride Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Diphenhydramine Hydrochloride Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
U.S. sales of Diphenhydramine Hydrochloride Injection, USP were approximately $17.2 million for the twelve months ending December 2025.1
Indications:
Diphenhydramine Hydrochloride Injection, USP is effective in adults and pediatric patients, for the following conditions when the oral form is impractical.
Antihistaminic
For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
For more information please visit, www.avenacy.com
